Farlong Nutraceutical Launches 90-Day Clinical Study to Determine Safety and Effectiveness of Farlong Lifeflower® Breviscapine

August 31, 2022

Results to demonstrate supplement’s effect on long and short-term memory, concentration, and clarity of thinking

Walnut, CA – Farlong Nutraceutical, a vertically integrated, plant-based ingredient and supplement company, is conducting a 90-day double blind, randomized, controlled, parallel study to determine the safety and effectiveness of Farlong Lifeflower® Breviscapine on improving long and short-term memory, concentration, and clarity of thinking in healthy individuals

LifeFlowerLed by clinician Melanie Montgomery, Ph.D., of LifeAlyze LLC, the partially grant-funded study consists of 160 healthy individuals divided into four study groups, with the first given one placebo capsule daily, and the other three groups to receive different daily doses of Farlong Lifeflower® Breviscapine – 100 mg, 200 mg, and 400 mg each.

“We are very excited to be underway with this clinical study, as we take pride in providing consumers and practitioners with data, research and studies that showcase the effect of our products and the positive impact they can have in changing peoples’ lives,” said Jing Struve, CEO and Executive Director of Farlong Nutraceutical.

Every 30 days, subjects will be given three separate evaluations to assess their cognitive thinking, concentration, clarity of thought and general brain functions, along with having vital signs checked and bloodwork analyzed. Farlong expects the study to be completed in November with results published soon thereafter.

Lifeflower® Breviscapine is an active flavonoid component extracted from Erigeron Breviscapus, containing more than 90 percent of scutellarin. Scutellarin has been shown to enhance memory, cognitive function and brain health; increase brain circulation; and promote the development of new blood vessels. A series of safety and efficacy studies were conducted, and an expert panel committee concluded that Lifeflower® Breviscapine manufactured consistent with cGMP (Current Good Manufacturing Practice) is GRAS based on scientific procedures for use as an ingredient in yogurt, nutritional bars, smoothies at 84 mg per serving, and dietary supplements at 200 mg per person per day.

About Farlong Nutraceutical:
Farlong is a science-based and vertically integrated functional ingredient and formula provider who has more than 24 years of experience focusing on discovering, developing, and providing safe, effective, and unique medicinal herbs, plant extracts, and formulas with its own GAP (Good Agricultural Practice) certified cultivation base, cGMP (Current Good Manufacturing Practice) certified manufacturing facilities and distribution channels. Combining ancient Oriental medicine and modern technology, Farlong develops its own line of natural supplement brands, while offering contract manufacturing services and ingredients for health and beauty companies to create proprietary formulas and product lines. For more information, visit Farlong.com for supplements and 400+ ingredients, and follow on Facebook, Twitter and Instagram.

Latest press releases